Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL; Division of Nephrology, Mayo Clinic, Jacksonville, Florida, United States of America; Department of Transplantation, Mayo Clinic, Jacksonville, Florida, United States of America.
Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL.
Mayo Clin Proc. 2022 Jun;97(6):1158-1163. doi: 10.1016/j.mayocp.2022.02.011.
Risk stratification of pulmonary embolism (PE) is vital for clinical management. While low-risk and high-risk PE management are clearly defined in many societal guidelines, the management of moderate-risk, also called submassive, PE remains unsettled. There is a subgroup of patients with submassive PE that progress to the severe category despite receiving systemic anticoagulation. The role of thrombolysis in the management of submassive PE remains to be established. We share our experience with ultra-low-dose (25-mg) systemic tissue plasminogen activator in a series of 4 patients with high-risk submassive PE.
肺栓塞（PE）的风险分层对临床管理至关重要。虽然许多社会指南都明确规定了低危和高危 PE 的管理，但中危（也称为亚大块）PE 的管理仍未确定。尽管接受了全身抗凝治疗，但仍有一部分亚大块 PE 患者进展为重症。溶栓在亚大块 PE 中的作用仍有待确定。我们分享了在 4 例高危亚大块 PE 患者中使用超低剂量（25 毫克）全身组织型纤溶酶原激活剂的经验。
